No Photo Available

Last Update

2016-11-26T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong M. First?

Dr. M. Roy First

Chief Medical Officer

Transplant Genomics Inc

Direct Phone: (773) ***-****       

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Company Description

Transplant Genomics Inc. (TGI) is a molecular diagnostics company committed to improving organ transplant outcomes, with an initial focus on kidney transplant recipients. Working with the transplant community, TGI is commercializing a suite of tests enabl ... more

Find other employees at this company (8)

Background Information

Employment History

Assistant Professor of Medicine In the Division of Nephrology

University of Cincinnati

President

American Society of Transplant Physicians

Vice President, Global Head, Transplantation

Astellas

Chairman

SAB

Affiliations

Renal Research Fellow
Michael Reese Hospital

Committee
Organ Donation Committee

Education

University of Witwatersrand

M.D.

advanced degrees

medicine

South Africa

Web References (60 Total References)


Leadership - Transplant Genomics

transplantgenomics.com [cached]

Dr. Roy First - Chief Medical Officer

M. Roy First, M.D. was Vice President and Global Therapeutic Area Leader, Transplantation at Astellas Pharma Global Development, Inc. After graduating from medical school at the University of Witwatersrand in Johannesburg, South Africa, he moved to Chicago in 1972 to take the position of Renal Research Fellow at the Michael Reese Hospital.
Read More In 1974, he was appointed Assistant Professor of Medicine in the Division of Nephrology at the University of Cincinnati, later becoming full Professor and Director of the Section of Transplantation, a position that he held until 2002, when he moved to Fujisawa (later Astellas). During his distinguished academic career, Dr. First has published more than 390 articles on transplantation, as well as 39 book chapters and two books. He is a past President of the American Society of Transplant Physicians (ASTP, subsequently AST) and has served on many United Network for Organ Sharing (UNOS) committees, including chairing the Organ Donation Committee, on the Center for Drug Evaluation and Research (CDER) of the Food and Drug Administration (FDA), as a reviewer for the National Institutes of Health (NIH), on the NIH Data Safety and Monitoring Board for Clinical Trials in Transplantation, and as a Councilor of the Transplantation Society. Dr. First has been on the editorial board of a number of journals including Transplantation, Transplantation Proceedings, Clinical Transplantation, the American Journal of Transplantation, and the Journal of the American Society of Nephrology. In 2013 he received the AST Lifetime Achievement Award.


Staff, Author at Nephrology News & Issues - Page 3 of 97

www.nephrologynews.com [cached]

Transplant Genomics hires Roy First, MD, as CMO Staff, May 22, 2015

Transplant Genomics has appointed transplant physician Roy First, MD, as its chief medical officer as the company moves toward the launch of its first product, the TruGraf Blood Test


Portfolio Company News - Dillon Capital LLC

dilloncapitalllc.com [cached]

Dr. Roy First Joins Transplant Genomics as Chief Medical Officer April 30, 2015


Our first collaborative project together ...

transplantgenomics.com [cached]

Our first collaborative project together is a case study in individualized medicine in which TruGraf will be used to support decisions around personalized immunosuppression," says Roy First, M.D., chief medical officer, Transplant Genomics.


TruGraf's ability to measure ...

transplantgenomics.com [cached]

TruGraf's ability to measure subclinical acute rejection as well as clinical acute rejection will provide an enabling metric to compare immunosuppressive performance," said Dr. Roy First, Chief Medical Officer, Transplant Genomics.

Similar Profiles

Other People with this Name

Other people with the name First

Glenn First
Keller Williams Realty Inc.

Barsha First
Smart Management Training & Consultancy

Lewis First
University of Vermont

Marilyn First
Washington State Board of Tax Appeals

Trish First
University of Michigan

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory